{{Cite journal| doi = 10.1161/JAHA.124.039164| issn = 2047-9980 (Electronic) 2047-9980 (Linking)| volume = 14| issue = 6| pages = –039164| last1 = Koechlin| first1 = L.| last2 = Boeddinghaus| first2 = J.| last3 = Lopez-Ayala| first3 = P.| last4 = Bianchi| first4 = C. L.| last5 = Nestelberger| first5 = T.| last6 = Wildi| first6 = K.| last7 = Miro| first7 = O.| last8 = Christ| first8 = M.| last9 = Rentsch| first9 = K.| last10 = Mahfoud| first10 = F.| last11 = Mueller| first11 = C.| last12 = dagger| first12 = Apace investigators| title = Impact of Food and Drug Administration Regulations on the Performance of Guideline-Recommended Pathways With an Approved Point-of-Care High-Sensitivity Cardiac Troponin I Assay| journal = J Am Heart Assoc| date = 2025-03-13| pmid = 40079304}}